News
Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...
Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...
Mounjaro – which competes in the market with Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) – was 8% better than ...
Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access and early detection remain limited.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results